SCA
LAB icon

Secor Capital Advisors’s Standard BioTools LAB Stock Holding History

Secor Capital Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50,610
Closed -$673K – 158
2019
Q1 		$673K Buy
+50,610
New +$533K 0.14% 221

Other funds holding LAB

EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Secor Capital Advisors's LAB Position: Q2 2019 in Review

Secor Capital Advisors sold out of Standard BioTools (LAB) in Q2 2019, closing a stake of 50,610 shares — an estimated $673K sold.

Secor Capital Advisors first reported a position in LAB in Q1 2019 and held it in 1 quarter. The position peaked at $673K in Q1 2019. 135 funds tracked by Wall St. Rank hold LAB as of Q2 2019.

  • Secor Capital Advisors reported no remaining Standard BioTools position as of Q2 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 50,610 Standard BioTools shares in Q2 2019, an estimated $673K.
  • Secor Capital Advisors first reported a position in Standard BioTools in Q1 2019 and held it in 1 quarter.
  • Secor Capital Advisors's Standard BioTools position peaked at $673K in Q1 2019.
  • 135 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2019.

Based on Secor Capital Advisors's 13F filing for Q2 2019.